Patent application number | Description | Published |
20100298568 | Processes and intermediates for preparing steric compounds - This invention relates to processes and intermediates for the preparation of an alpha-amino beta-hydroxy acid of Formula 1 | 11-25-2010 |
20110071074 | DEUTERATED HEPATITIS C PROTEASE INHIBITORS - A deuterated α-ketoamido steric specific compound of the formula | 03-24-2011 |
20130102782 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES - The present invention relates to processes and intermediates for the preparation of compounds useful as inhibitors of Janus kinases (JAK). | 04-25-2013 |
20130131359 | PROCESSES AND INTERMEDIATES FOR PREPARING STERIC COMPOUNDS - This invention relates to processes and intermediates for the preparation of an alpha-amino beta-hydroxy acid of Formula 1 | 05-23-2013 |
20130253181 | METHODS OF PREPARING SUBSTITUTED NUCLEOTIDE ANALOGS - Disclosed herein are methods of preparing a phosphorothioate nucleotide analog, which are useful in treating diseases and/or conditions such as viral infections. | 09-26-2013 |
20130266538 | Solid Forms of a Thiophosphoramidate Nucleotide Prodrug - The present application relates to solid state forms, for example, crystalline forms of 2′-C-methyluridine-5′-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, pharmaceutical compositions that can include one or more solid forms of 2′-C-methyluridine-5′-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, and methods of treating or ameliorating diseases and/or conditions with one or more solid forms of 2′-C-methyluridine-5′-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate. Also disclosed herein are methods of treating diseases and/or conditions with one or more solid forms of 2′-C-methyluridine-5′-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate in combination with one or more other agents. | 10-10-2013 |
20130281687 | METHODS OF PREPARING SUBSTITUTED NUCLEOTIDE ANALOGS - Disclosed herein are methods of preparing a phosphorothioate nucleotide analog, which are useful in treating diseases and/or conditions such as viral infections. | 10-24-2013 |
20130303764 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES - The present invention relates to processes and intermediates for the preparation of compounds useful as inhibitors of Janus kinases (JAK). | 11-14-2013 |
20130324743 | PROCESS OF PRODUCING CYCLOALKYLCARBOXAMIDO-INDOLE COMPOUNDS - The present invention features processes for preparing compounds, such as (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide (Compound 1), useful for treating CFTR mediated diseases such as cystic fibrosis. | 12-05-2013 |
20140154210 | Solid Forms of a Thiophosphoramidate Nucleotide Prodrug - The present application relates to solid state forms, for example, crystalline forms of 2′-C-methyluridine-5′-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, pharmaceutical compositions that can include one or more solid forms of 2′-C-methyluridine-5′-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, and methods of treating or ameliorating diseases and/or conditions with one or more solid forms of 2′-C-methyluridine-5′-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate. Also disclosed herein are methods of treating diseases and/or conditions with one or more solid forms of 2′-C-methyluridine-5′-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate in combination with one or more other agents. | 06-05-2014 |
20140309413 | METHODS OF STEREOSELECTIVE SYNTHESIS OF SUBSTITUTED NUCLEOSIDE ANALOGS - The present invention relates to the novel diastereoselective syntheses for generating phosphorothioate compounds. Examples include nucleoside phosphorothioate analogs that are useful in treating diseases and/or conditions such as viral infections. | 10-16-2014 |
20140309421 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES - The present invention relates to processes and intermediates for the preparation of compounds useful as inhibitors of Janus kinases (JAK). | 10-16-2014 |